▸✏️ Help fill in this profile
📡 Recent posts· 0
📊 Financial
▾ 📰 Recent news
-
Which dow jones stocks are moving on Monday?Join us in exploring the top gainers and losers within the dow jones index one hour before the close of the markets on Monday as we examine the latest happenings in today's session.
-
Top dow jones movers in Monday's session
Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Monday.
-
Merck Stock’s New Drugs Were Already Answering The Big QuestionWhile Wall Street fretted over the future of its biggest blockbuster, a pair of new drugs were already showing the company's next act was well underway.
-
AbbVie and Merck Face-Off: Which Pharma Stock Has the Lead?
ABBV's successful transition beyond Humira and growth from newer medicines give it an edge over MRK in this oncology-immunology showdown.
-
Questex’s DPHARM Announces Senior Leadership and Keynotes for the 16th Annual Conference
BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- DPHARM, the leading innovation event for clinical trial operation executives, announces the 16th annual conference agenda including its senior leadership and keynotes. DPHARM …
-
Sanofi swaps R&D leaders; Merck’s Prometheus deal pays dividends
Houman Ashrafian is leaving Sanofi to pursue a new opportunity. Elsewhere, one of Merck’s prized immune drugs succeeded in a pivotal study and a psychedelics biotech’s shares surged.
-
Merck (MRK) Wins FDA Expansions, Posts HIV Data, And Ends Lung Cancer Trial
Merck (NYSE:MRK) received FDA approval for expanded use of KEYTRUDA and KEYTRUDA QLEX with WELIREG as adjuvant treatment in certain renal cell carcinoma patients. The FDA also granted expanded approval for CAPVAXIVE i…
-
Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
RAHWAY, N.J., June 22, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 ATLAS-UC induction-only study (Study 2) evaluating tuliso…
▾ 🧱 Sum of the parts
| Name | Type | % stake | Paid | Annual rev | Now worth | ×% our share | Note |
|---|---|---|---|---|---|---|---|
| Pharmaceuticals | 🧩 segment | 100.0% | — | $53.0B | $300.0B | $300.0B | Human health pharmaceutical products, including oncology, vaccines, hospital acute care, and other specialty products. |
| Animal Health | 🧩 segment | 100.0% | — | $5.8B | $60.0B | $60.0B | Veterinary pharmaceutical products and services, including vaccines, parasiticides, and other animal health products. |
| Other | 🧩 segment | 100.0% | — | $0.5B | $5.0B | $5.0B | Primarily includes third-party manufacturing arrangements and other miscellaneous activities. |
| Other | 🧩 segment | 100.0% | — | — | — | — | holdings not assigned to a reported segment |
| Acceleron Pharma · acq. 2021 | 🏢 subsidiary | 100.0% | $11.5B | — | $11.5B | $11.5B | Biopharmaceutical company focused on rare diseases, acquired for its pulmonary hypertension drug sotatercept.(acquisition price) |
| ArQule, Inc. · acq. 2020 | 🏢 subsidiary | 100.0% | $2.7B | — | $2.7B | $2.7B | Acquired for its oncology pipeline, including BTK inhibitor program.(acquisition price) |
| Cube Pharmaceuticals | 🏢 subsidiary | 100.0% | — | — | — | — | Internally developed subsidiary focused on antibiotic research, now integrated into Merck's R&D.(estimate) |
| Immune Design Corp. · acq. 2019 | 🏢 subsidiary | 100.0% | — | — | — | — | Acquired for its immunotherapy technologies, integrated into Merck's oncology pipeline.(acquisition price) |
| Prometheus Biosciences · acq. 2023 | 🏢 subsidiary | 100.0% | $10.8B | — | $10.8B | $10.8B | Biotechnology company focused on inflammatory bowel disease, acquired for its lead candidate PRA023.(acquisition price) |
| Affirmative Investment Management (AIM) | 💼 minority stake | — | — | — | — | — | Merck's venture capital arm, investing in early-stage biotech and life sciences companies. Internally built, no direct acquisition price.(internally built) |
| Moderna 📈 MRNA $59.35-7.22% · acq. 2015 | 💼 minority stake | 0.5% | $0.1B | — | $25.4B | $0.1B | Merck made an equity investment in Moderna in 2015 and 2018, collaborating on mRNA-based vaccines and therapies.(live market cap) |
| Organon & Co. 📈 OGN $13.40-0.22% · acq. 2021 | 💼 minority stake | — | — | — | $3.5B | $3.5B | Spun off in 2021, focusing on women's health, biosimilars, and established brands. Merck no longer holds a material stake.(live market cap) |
▾ 📅 Calendar & events
No events yet. For public companies, earnings dates auto-populate. For private ones, anyone signed in can add events.
▾
💼 Famous stockholders
Institutional funds holding this stock per their most-recent SEC 13F filing. Click a fund name to jump to that investor's shadow page.
📚 Books · 2
🎥 Playlists featuring Merck · 0
➕ Sign in to add a playlist. It surfaces here, on your personal playlists page, and on every twin course at every school.
▸📺 Videos
· 8 · refreshed 2026-06-12 13:36
Top YouTube results for Merck.
➕ Suggest a YouTube video
Your suggestion appears immediately for all visitors. Must be a public YouTube video relevant to Merck.
Quotes· 0
⭐ Reviews · 0
Replies ingeneral· 0
Every shadow page is its own thread. Add a thought, reply to others, come back later.